-+ 0.00%
-+ 0.00%
-+ 0.00%

ACTINIUM PHARMACEUTICALS ANNOUNCES ENROLLMENT IN THE RADIANZ IMAGING CLINICAL TRIAL INTENDED TO DEMONSTRATE THE PAN-CANCER POTENTIAL OF ATNM-400, A FIRST-IN-CLASS HER3-TARGETING RADIOTHERAPY

Reuters·11/11/2026 13:02:55